Early versus late preemptive allogeneic hematopoietic cell transplantation for relapsed or refractory acute myeloid leukemia

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 9, 2014, Pages 1369-1374

  Chen, George L ^a   Liu, Hong ^a   Zhang, Yali ^a   Thomas, Julie ^a   Ross, Maureen ^a   Wang, Eunice S ^a   Block, AnneMarie W ^a   Sait, Sheila ^a   Deeb, George ^a   Wallace, Paul ^a   Wetzler, Meir ^a   Hahn, Theresa ^a   McCarthy, Philip L ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Allogeneic hematopoietic cell transplant; Hypoplasia; Relapsed or refractory AML

Indexed keywords

ANTHRACYCLINE; CYTARABINE; ETOPOSIDE; GEMTUZUMAB; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; GRAFT VERSUS LEUKEMIA EFFECT; HIGH RISK PATIENT; HUMAN; LEUKEMIA RELAPSE; OVERALL SURVIVAL; PATIENT SAFETY; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; ADVERSE EFFECTS; ALLOTRANSPLANTATION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; TUMOR RECURRENCE; YOUNG ADULT;

ADOLESCENT; ADULT; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84906101663     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.05.013     Document Type: Article

References (18)

1. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976, 33:451-458.
2. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985, 103:620-625.
3. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). Br J Haematol 1991, 78:325-329.
4. Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000, 96:4075-4083.
5. Duval M., Klein J.P., He W., et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. JClin Oncol 2010, 28:3730-3738.
6. Chen G.L., Zhang Y., Hahn T., et al. Acute GVHD prophylaxis with standard-dose, micro-dose or no MTX after fludarabine/melphalan conditioning. Bone Marrow Transplant 2014, 49:248-253.
7. Armistead P.M., de Lima M., Pierce S., et al. Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia. Biol Blood Marrow Transplant 2009, 15:1431-1438.
8. Craddock C., Labopin M., Pillai S., et al. Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia 2011, 25:808-813.
9. Todisco E., Ciceri F., Oldani E., et al. The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo. Leukemia 2013, 27:2086-2091.
10. Rollig C., Thiede C., Gramatzki M., et al. Anovel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. Blood 2010, 116:971-978.
11. Grimwade D., Hills R.K., Moorman A.V., et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010, 116:354-365.
12. Burnett A.K., Hills R.K., Hunter A.E., et al. The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. Leukemia 2013, 27:75-81.
13. Burnett A.K., Russell N.H., Hills R.K., et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. JClin Oncol 2012, 30:3924-3931.
14. Burnett A.K., Hills R.K., Milligan D., et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. JClin Oncol 2011, 29:369-377.
15. Wang E.S., Zeidan A., Tan W., et al. Cytoreduction with gemtuzumab ozogamicin and cytarabine prior to allogeneic stem cell transplant for relapsed/refractory acute myeloid leukemia. Leuk Lymphoma 2012, 53:2085-2088.
16. Armand P., Kim H.T., Cutler C.S., et al. Aprognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008, 14:28-35.
17. Berman E., Little C., Gee T., et al. Reasons that patients with acute myelogenous leukemia do not undergo allogeneic bone marrow transplantation. NEngl J Med 1992, 326:156-160.
18. Wetzler M., Andrews C., Ford L.A., et al. Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia. Cancer 2011, 117:4861-4868.